Briacell Therapeutics Corp (BCTX) Stock Price, Quote & News

Company Profile

BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agree...

Industry: Biotechnology

Sector: Healthcare

Phone: 604 921 1810

Fax: 604 921 1898

Website: briacell.com

Address:

Bellevue Centre, Suite 300 235 -15th Street, West Vancouver, Canada

PML1 Jul. 5 at 8:19 PM

$BCTX Bullish The trial design is brilliant. Upon interim readout after 144 deaths occur, Briacell may receive FDA approval if they show 40% reduction in mortality. If they don't show 40% reduction in mortality, they may continue study and receive FDA approval if they show 30% reduction in mortality. In addition, after initial interim readout, they have opportunity to tweak study design and focus on that subgroup of patients most likely to derive benefit from the drug or comtinue trial unchanged. A lot of flexibility after initial interim readout. In addition, Briacell has specific subgroups that will be evaluated (e.g. patients in which cancer has spread to brain). This is another shot on goal that may lead to FDA approval. I'm very bullish because we have several opportunities for Briacell to deliver results that may lead to FDA approval. The recent Renmark presentation provides details on this.

1 · Reply

Stonehands Jul. 3 at 12:19 PM

$BCTX this has been a terrible stock for longs and a great stock for traders. Buy after offering, sell immediately on postive PR. Rinse and repeat. That will change sometime over the next year. I fully expect another offering, but full approval will re-rate this much, much higher. Traders might be on the outside looking in. Anyone holding a core and trading around that?

2 · Reply

PML1 Jul. 2 at 10:52 PM

$BCTX Bullish Renmark presentation is now up and available for viewing. I'm extremely bullish on Briacell prospects. With favorable Phase 3 interim readout, BCTX could potentially increase 10x or 20x current share price based on very small float and enormous market potential. https://renmark-drupal.s3.amazonaws.com/vndr/briacell-therapeutics-corp/2026-06-25-11-00-00/index.html

5 · Reply

rp6577 Jul. 2 at 6:35 PM

$BCTX people are starting to realise that we are on the cusp of a phase 3 readout which could easily send it 10x, 20x or more $XBI

0 · Reply

rp6577 Jul. 2 at 6:17 PM

$BCTX nice recovery

0 · Reply

dhadad64 Jul. 2 at 5:31 PM

$BCTX lol . They get you thinking your gonna make money and then the rug pull .

1 · Reply

diggs24 Jul. 2 at 5:23 PM

$BCTX Added 1000@$3.15

0 · Reply

JediGreen Jul. 2 at 4:17 PM

$BCTX Renmark Virtual Non-Deal Roadshow: TSX - BCT | NASDAQ - BCTX (ID 2997) https://renmark-drupal.s3.amazonaws.com/vndr/briacell-therapeutics-corp/2026-06-25-11-00-00/index.html

1 · Reply

JediGreen Jul. 2 at 4:15 PM

$BCTX

0 · Reply

JediGreen Jul. 2 at 4:15 PM

$BCTX Renmark Virtual Non-Deal Roadshow: TSX - BCT | NASDAQ - BCTX | VNDR Library | Renmark https://www.renmarkfinancial.com/vndrs/renmark-virtual-non-deal-roadshow-tsx-bct-nasdaq-bctx-2026-06-25-110000

0 · Reply

BriaCell Partners With Uneedle To Support Scalable Microneedle Delivery Of Bria-IMT

2026-06-25T13:25:58.000Z - 10 days ago

BriaCell (BCTX) Partners with Uneedle for Microneedle Technology Development

2026-06-25T11:45:30.000Z - 10 days ago

BriaCell enters MoU with Uneedle for microneedle technology

Thu, 25 Jun 2026 07:30:00 -0400 - 10 days ago

BriaCell Partners with Uneedle for Scalable Microneedle Administration of Bria-IMT™

Tue, 02 Jun 2026 16:05:00 -0400 - 4 weeks ago

BriaCell Therapeutics Announces Closing of Offering

Mon, 01 Jun 2026 07:30:00 -0400 - 4 weeks ago

BriaCell Presents Positive Clinical Data at ASCO 2026

Sun, 31 May 2026 19:59:00 -0400 - 5 weeks ago

BriaCell Therapeutics Announces Pricing of Offering

2026-05-26T14:43:01.000Z - 5 weeks ago

BriaCell (BCTX) Receives Positive Update from Data Safety Monitoring Board

2026-05-26T13:05:39.000Z - 5 weeks ago

BriaCell receives recommendation for DSMB for Phase 3 Bria-ABC study

Tue, 26 May 2026 07:30:00 -0400 - 5 weeks ago

BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer

2026-05-22T13:27:19.000Z - 6 weeks ago

BriaCell (BCTX) Unveils Key Clinical Data at ASCO Annual Meeting 2026

2026-05-22T11:49:02.000Z - 6 weeks ago

BriaCell announces data from Bria-IMT at ASCO 2026

Fri, 22 May 2026 07:30:00 -0400 - 6 weeks ago

BriaCell Presentations Highlight Positive Clinical Data for Bria-IMT™ at ASCO 2026

Fri, 15 May 2026 07:30:00 -0400 - 7 weeks ago

BriaCell Expands Pipeline to Include an Ovarian Cancer Immunotherapy Candidate, Bria-OVA+™

2026-05-14T15:31:53.000Z - 7 weeks ago

BriaCell (BCTX) Completes Manufacturing for New Prostate Cancer Treatment

Thu, 14 May 2026 07:30:00 -0400 - 7 weeks ago

BriaCell Completes Manufacturing of Clinical Supplies of Bria-PROS+™ for Prostate Cancer

2026-05-13T16:39:28.000Z - 7 weeks ago

BriaCell (BCTX) Expands Clinical Trial Network for Advanced Breast Cancer Treatment

2026-05-13T14:41:55.000Z - 7 weeks ago

BriaCell adds Penn Medicine as Phase 3 breast cancer study site

Wed, 13 May 2026 07:30:00 -0400 - 7 weeks ago

BriaCell Adds Penn Medicine's Abramson Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study

Tue, 12 May 2026 07:30:00 -0400 - 7 weeks ago

BriaCell Phase 3 Bria-IMT™ Study Enrollment Surpasses 230 Patients

Thu, 07 May 2026 07:30:00 -0400 - 2 months ago

BriaCell Adds NYU Langone Health's Perlmutter Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study

2026-05-07T04:03:56.000Z - 2 months ago

BriaCell receives FDA clearance to initiate Bria-BRES+ trial

Wed, 06 May 2026 07:30:00 -0400 - 2 months ago

BriaCell Receives FDA Clearance to Initiate Bria-BRES+™ Clinical Study in Breast Cancer

Mon, 27 Apr 2026 07:30:00 -0400 - 2 months ago

BriaCell Announces Six Clinical Data Presentations at ASCO 2026

2026-04-21T13:28:43.000Z - 2 months ago

BriaCell (BCTX) Showcases Promising Data at AACR Annual Meeting

2026-04-21T11:54:23.000Z - 2 months ago

BriaCell presents anti-cancer activity of Bria-OTS

Tue, 21 Apr 2026 07:30:00 -0400 - 2 months ago

BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ in Preclinical Cancer Models

2026-04-20T13:32:04.000Z - 2 months ago

BriaCell (BCTX) Showcases Positive Clinical Data at AACR Annual Meeting

2026-04-20T11:41:56.000Z - 2 months ago

BriaCell presents Phase 3 quality of life, Phase 2 biomarker data at AACR

Mon, 20 Apr 2026 07:30:00 -0400 - 2 months ago

BriaCell Presents Positive Phase 3 Quality of Life and Phase 2 Biomarker Data at the 2026 AACR Meeting

Tue, 31 Mar 2026 16:05:00 -0400 - 3 months ago

BriaCell and BriaPro Announce Closing of Asset Purchase Transaction for Exclusive Soluble CD80 License

2026-03-18T13:30:56.000Z - 3 months ago

BriaCell (BCTX) to Reveal Key Findings at 2026 AACR Annual Meeting

2026-03-18T11:42:55.000Z - 3 months ago

BriaCell to present four posters at the 2026 AACR

Wed, 18 Mar 2026 07:30:00 -0400 - 3 months ago

BriaCell to Present Positive Clinical Data for Bria-IMT™ and Preclinical Data for Next Generation Bria-OTS+™ Personalized Immunotherapy at the 2026 AACR Conference

Tue, 10 Mar 2026 07:30:00 -0400 - 4 months ago

BriaCell to Present Four Poster Presentations at the 2026 AACR Annual Meeting

Thu, 05 Mar 2026 16:04:00 -0500 - 4 months ago

BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting

2026-02-18T22:51:30.000Z - 4 months ago

BriaCell (BCTX) Expands Biologic Cancer Treatments Through New Agreement

2026-02-18T22:35:25.000Z - 4 months ago

BriaPro to purchase BriaCell’s license to develop, commercialize sCD80

Wed, 18 Feb 2026 17:30:00 -0500 - 4 months ago

BriaCell and BriaPro Enter Into Asset Purchase Agreement for Exclusive Soluble CD80 License

2026-02-17T12:40:59.000Z - 4 months ago

BriaCell receives positive recommendation from DSMB for Phase 3 Bria-ABC study

Tue, 17 Feb 2026 07:30:00 -0500 - 4 months ago

BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer

2026-01-28T13:30:56.000Z - 5 months ago

BriaCell Therapeutics (BCTX) Shows Promising Results in Metastatic Breast Cancer Treatment

2026-01-28T12:40:40.000Z - 5 months ago

BriaCell says patient images show regression, resolution of metastsized tumors

Wed, 28 Jan 2026 07:30:00 -0500 - 5 months ago

BriaCell Patients' Images Show Regression and Resolution of Metastasized Tumors and Immune Activation

2026-01-27T13:32:37.000Z - 5 months ago

BriaCell (BCTX) Reports Promising Phase 2 Survival Data

2026-01-27T12:41:04.000Z - 5 months ago

BriaCell extends 18-47 month survival in Phase 2 metastatic breast cancer

Tue, 27 Jan 2026 07:30:00 -0500 - 5 months ago

BriaCell Highlights Extended >18-47 Months Survival in Phase 2 Metastatic Breast Cancer Patients

2026-01-19T16:00:45.000Z - 5 months ago

Is the Market Bullish or Bearish on BriaCell Therapeutics Corp?

2026-01-16T13:58:57.000Z - 6 months ago

Weekly Buzz: LYRA Slashes Jobs; FDA Okays FBIO's ZYCUBO; BSX To Acquire PEN; BCTX On Watch

Thu, 15 Jan 2026 16:05:00 -0500 - 6 months ago

BriaCell Therapeutics Announces Closing of US$30 million Public Offering

Jan 13, 2026, 9:00 PM EST - 6 months ago

BriaCell Therapeutics Announces Pricing of $30 million Public Offering

2026-01-13T14:41:11.000Z - 6 months ago

BriaCell Therapeutics trading resumes

2026-01-13T14:35:29.000Z - 6 months ago

BriaCell Therapeutics trading halted, volatility trading pause

2026-01-13T12:35:49.000Z - 6 months ago

BriaCell reports sustained complete resolution of lung metastasis in Bria-OTS

Jan 13, 2026, 7:30 AM EST - 6 months ago

BriaCell Reports Sustained Complete Resolution of Lung Metastasis in Bria-OTS™ Patient

Dec 18, 2025, 7:30 AM EST - 7 months ago

“Eleven clinical trials that will shape medicine in 2026” – BriaCell Phase 3 Trial Featured in Nature Medicine

2025-12-10T12:41:29.000Z - 7 months ago

BriaCell presents Phase 2, Phase 3 data on Bria-IMT at SABCS 2025

Dec 10, 2025, 7:30 AM EST - 7 months ago

BriaCell Presents Outstanding Phase 2 Survival & Promising Phase 3 Clinical Data at SABCS® 2025

2025-12-09T12:35:35.000Z - 7 months ago

BriaCell announces Phase 3 patient enrollment on track for 1H26 data readout

Dec 9, 2025, 7:30 AM EST - 7 months ago

BriaCell's Phase 3 Patient Enrollment on Track for 1H2026 Topline Data Readout

2025-12-02T12:36:29.000Z - 7 months ago

BriaCell to present Phase 2 survival, Phase 3 data at SABCS 2025

Dec 2, 2025, 7:30 AM EST - 7 months ago

BriaCell to Present Phase 2 Survival & Phase 3 Clinical Data at SABCS® 2025

Nov 25, 2025, 7:30 AM EST - 7 months ago

BriaCell to Highlight Positive Phase 2 & Phase 3 Clinical Data at SABCS® 2025

Nov 20, 2025, 7:30 AM EST - 8 months ago

BriaCell and Receptor.AI to Collaborate on AI Driven Small Molecule Cancer Therapeutics

Nov 18, 2025, 7:30 AM EST - 8 months ago

BriaCell Selected to Present Phase 2 & 3 Clinical Data at SABCS® 2025

Nov 7, 2025, 7:30 AM EST - 8 months ago

BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ at SITC 2025

Nov 4, 2025, 7:30 AM EST - 8 months ago

BriaCell to Present Robust Anti-Cancer Activity of Bria-OTS+™ in Breast and Prostate Cancer Models

Oct 21, 2025, 7:50 AM EDT - 9 months ago

BriaCell Adds Key Clinical Sites in Phase 3 Metastatic Breast Cancer Study

Oct 21, 2025, 7:30 AM EDT - 9 months ago

BriaCell Announces Collaboration with MSK Accelerator to Advance Bria-OTS+™ for Breast Cancer

Oct 20, 2025, 7:30 AM EDT - 9 months ago

BriaCell Presents Phase 3 Clinical Biomarker Data at ESMO 2025

Oct 13, 2025, 7:30 AM EDT - 9 months ago

BriaCell to Present Positive Clinical Biomarker Data of Phase 3 Study at ESMO 2025

Oct 3, 2025, 7:30 AM EDT - 9 months ago

BriaCell to Present Bria-OTS+™ Preclinical Data at SITC 2025 Annual Meeting

Aug 26, 2025, 7:30 AM EDT - 11 months ago

BriaCell's Bria-OTS+™ Mechanism of Action Validated in Highly Rated Peer Reviewed Cancer Journal

Aug 25, 2025, 7:30 AM EDT - 11 months ago

BriaCell Awarded $2 Million NCI Grant to Advance Bria-PROS+™ in Prostate Cancer

Aug 21, 2025, 12:00 PM EDT - 11 months ago

BriaCell Announces Proposed Effective Date of Share Consolidation

Aug 13, 2025, 7:30 AM EDT - 11 months ago

BriaCell Selected for MSK's 2025 Therapeutics Accelerator Program for Bria-OTS+™ for Cancer

Jul 31, 2025, 7:30 AM EDT - 1 year ago

BriaCell Adds UCLA Health as Key Site in Pivotal Phase 3 Breast Cancer Study

Jul 30, 2025, 7:30 AM EDT - 1 year ago

BriaCell Awarded New Zealand Patent for its Whole Cell Technology

Jul 29, 2025, 7:30 AM EDT - 1 year ago

BriaCell's Subsidiary, BriaPro, Files Patent Application for Immuno-Oncology Platform with Novel Multitargeting Agents

Jul 25, 2025, 7:30 AM EDT - 1 year ago

BriaCell Announces Two Clinical Data Poster Presentations at ESMO 2025

Jul 16, 2025, 4:05 PM EDT - 1 year ago

BriaCell Therapeutics Announces Closing of $15 million Public Offering

Jul 15, 2025, 3:05 PM EDT - 1 year ago

BriaCell Therapeutics Announces Pricing of $15 million Public Offering

Jul 15, 2025, 7:30 AM EDT - 1 year ago

BriaCell Adds Mayo Clinic to Phase 3 Study in Metastatic Breast Cancer

PML1 Jul. 5 at 8:19 PM

1 · Reply

Stonehands Jul. 3 at 12:19 PM

2 · Reply

PML1 Jul. 2 at 10:52 PM

5 · Reply

rp6577 Jul. 2 at 6:35 PM

$BCTX people are starting to realise that we are on the cusp of a phase 3 readout which could easily send it 10x, 20x or more $XBI

0 · Reply

rp6577 Jul. 2 at 6:17 PM

$BCTX nice recovery

0 · Reply

dhadad64 Jul. 2 at 5:31 PM

$BCTX lol . They get you thinking your gonna make money and then the rug pull .

1 · Reply

diggs24 Jul. 2 at 5:23 PM

$BCTX Added 1000@$3.15

0 · Reply

JediGreen Jul. 2 at 4:17 PM

$BCTX Renmark Virtual Non-Deal Roadshow: TSX - BCT | NASDAQ - BCTX (ID 2997) https://renmark-drupal.s3.amazonaws.com/vndr/briacell-therapeutics-corp/2026-06-25-11-00-00/index.html

1 · Reply

JediGreen Jul. 2 at 4:15 PM

$BCTX

0 · Reply

JediGreen Jul. 2 at 4:15 PM

0 · Reply

Goodstockday Jul. 2 at 3:57 PM

$BCTX I will never understand price action like this. If this stock gets phase 3 results similar to phase 2, it is worth $30+. Yes, this requires taking some risk. However, the rewards are amazing. No casino or sports book is going to offer you odds this imbalanced. The response of the market: down 8% and crying about the recent 5 million dilution for a company that could be worth billions.

1 · Reply